SCHEMBL16185151

SCHEMBL16185151

CNc1nc(-c2ccccn2)nc2c(OC)cc(-c3cc(F)ccc3F)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.45
▸ SMN1; SMN2 Q16637 5/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ LMNA P02545 4/20 0.43
▸ KDM4E B2RXH2 4/20 0.43
▸ HSD17B10 Q99714 3/20 0.43
▸ ABCB1 P08183 2/20 0.43
▸ ABCG2 Q9UNQ0 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ CYP2D6 P10635 2/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ HTT P42858 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ PPP1CA P62136 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ GRM5 P41594 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14474671 0.92 L3MBTL1 (0.47) L3MBTL1SMN1; SMN2ALDH1A1LMNAKDM4E
SCHEMBL16185123 0.91 LMNA (0.46) L3MBTL1SMN1; SMN2ALDH1A1LMNAKDM4E
SCHEMBL16185154 0.91 GRM5 (0.42) L3MBTL1SMN1; SMN2LMNAKDM4EHTT
SCHEMBL14474200 0.90 CYP1A2 (0.41) SMN1; SMN2ALDH1A1LMNAKDM4EHSD17B10
SCHEMBL14474182 0.89 ABCB1 (0.47) L3MBTL1SMN1; SMN2ALDH1A1LMNAKDM4E
SCHEMBL16185152 0.88 SCN9A (0.42) SMN1; SMN2ALDH1A1LMNAKDM4EHSD17B10
SCHEMBL16184198 0.88 TGFBR1 (0.38) L3MBTL1SMN1; SMN2ALDH1A1LMNAKDM4E
SCHEMBL14474190 0.88 LMNA (0.38) L3MBTL1SMN1; SMN2ALDH1A1LMNAKDM4E
SCHEMBL14474188 0.87 ABCB1 (0.47) L3MBTL1SMN1; SMN2ALDH1A1LMNAKDM4E
SCHEMBL14474674 0.86 SMN1; SMN2 (0.43) L3MBTL1SMN1; SMN2ALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB L3MBTL1 2587/4885SMN1; SMN2 3987/4885ALDH1A1 1687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback